BioStock: New data strengthens Follicum’s diabetes project

Follicum, a company that develops tissue repair peptides, has advanced further in its preclinical work with developing a drug candidate for the treatment of diabetes. Through extensive and advanced experimental work, the company believes that the peptides bind to a specific receptor in the membranes of cells that are considered to play an important role in the protection and repair of organ tissue. BioStock has contacted Follicum’s CEO Jan Alenfall to learn more about what this means for the project.

Read the full article at biostock.se:

https://www.biostock.se/en/new-data-strengthens-follicums-diabetes-project/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se